课题基金 / 基金详情

The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer

The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer
无机紫外线滤光剂的开发可改善人体皮肤的局部保留,从而预防皮肤癌
批准号:
10080275
负责人:
Steven Isaacman
金额:
$100.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-18 至 2022-06-30

项目摘要

项目成果

Steven Isaacman的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY / ABSTRACT This Phase II project is predicated on the NCI Phase I award 1R43CA236265-01 and is a resubmission. Problem to be Solved and Significance: Exposure to Ultraviolet radiation (UVR) is a risk factor for the development of skin cancer, and health care agencies recommend that sunscreens be used as a preventative measure. A major limitation of commercial sunscreens is the need to continually reapply to gain full benefit. This is because sunscreens contain UV filters that lack affinity with skin and are easily removed by normal wear. The development of durable filters with improved retention on skin has the potential to mitigate UV- mediated toxicities and remains a significant priority. Product and Long-Term Goal: Nanometics (d.b.a. PHD Biosciences [PHD]) is developing novel titanium dioxide and zinc oxide UV filters that contain a coating that interacts with skin proteins to improve topical retention time for up to 160 min. The novel UV filters are as photoprotective and safe as commercial UV filters and readily synthesized from inexpensive starting materials. They will be sold globally as ingredients for sunscreens and other topical products. It is anticipated that these UV filters will alleviate the need for constant product reapplication. Technological Innovation: The surface of commercial titanium dioxide and zinc oxide UV filters is covalently modified to contain a coating that interacts with skin proteins to improve topical retention time. The coating is designed to form a stable interaction at skin pH and can easily be removed by washing with soap and water. Specific Aim #1 Demonstrate that modification with HPGA does not influence the dermal penetration profile of the UV filters when evaluated on human skin explants. In this aim the dermal penetration profile of HPGA-Filters on cultured human skin will be investigated. Success Criterion: This aim will be successful upon determining that the HPGA-Filters do not penetrate to viable skin cells after a 48 h evaluation period. Specific Aim #2. Scale the chemistry, manufacturing and control processes to produce the HPGA-Filters on 75 kilogram batch sizes. The chemistry, manufacturing, and control (CMC) processes to produce HPGA-Filters in 75 kg batch sizes will be developed. Success Criterion: This aim will be successful upon optimizing the procedure to produce materials at 75 kg batch sizes with reproducible analytical profile and stability. Commercial Opportunity: The global market for UV filters is estimated to exceed $650 million by 2019. Phase II SBIR studies will include additional studies to confirm the safety on a larger number of volunteers; examine the performance against leading commercial sunscreens; and optimize the chemistry, manufacturing, and control (CMC) processes to produce the filters in multi-kilogram quantities. The technology is covered by a pending patent that protects the PHD commercial and development interests.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis
  • 批准号:
    10820810
  • 项目类别:
  • 资助金额:
    $100.0万
  • 财政年份:
    2023
  • 负责人:
    Steven Isaacman
  • 依托单位:
Furthering the clinical development of a first in class, water resistant sunscreen to meet emerging environmental regulations
  • 批准号:
    10255409
  • 项目类别:
  • 资助金额:
    $39.88万
  • 财政年份:
    2021
  • 负责人:
    Steven Isaacman
  • 依托单位:
The Development of Inorganic Ultraviolet Filters Exhibiting Improved Topical Retention on Human Skin for The Prevention of Skin Cancer
  • 批准号:
    10202504
  • 项目类别:
  • 资助金额:
    $100.0万
  • 财政年份:
    2018
  • 负责人:
    Steven Isaacman
  • 依托单位:
A targeted immunomodulator for the treatment of acute sickle crisis
  • 批准号:
    8979976
  • 项目类别:
  • 资助金额:
    $22.49万
  • 财政年份:
    2015
  • 负责人:
    Steven Isaacman
  • 依托单位:
海外基金